An Updated Economic Analysis of the Global Polio Eradication Initiative

被引:20
作者
Thompson, Kimberly M. [1 ]
Kalkowska, Dominika A. [1 ]
机构
[1] Kid Risk Inc, 7512 Dr Phillips Blvd 50-523, Orlando, FL 32819 USA
关键词
Cost; eradication; polio; POLIOMYELITIS; WORLDWIDE; VACCINE;
D O I
10.1111/risa.13665
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Despite a strong global commitment, polio eradication efforts continue now more than 30 years after the 1988 World Health Assembly resolution that established the Global Polio Eradication Initiative (GPEI), and 20 years after the original target of the year 2000. Prior health economic analyses estimated incremental net benefits of the GPEI of 40-50 billion in 2008 U.S. dollars (US$2008, equivalent to 48-59 billion US$2019), assuming the achievement of polio eradication by 2012. Given the delays in achieving polio eradication and increased costs, we performed an updated economic analysis of the GPEI using an updated integrated global model, and considering the GPEI trajectory as of the beginning of 2020. Applying similar methods and assuming eradication achievement in 2023, we estimate incremental net benefits of the GPEI of 28 billion US$2019, which falls below the prior estimate. Delays in achieving polio eradication combined with the widescale introduction of relatively expensive inactivated poliovirus vaccine significantly increased the costs of the GPEI and make it less cost-effective, although the GPEI continues to yield expected incremental net benefits at the global level when considered over the time horizon of 1988-2029. The overall health and financial benefits of the GPEI will depend on whether and when the GPEI can achieve its goals, when eradication occurs, the valuation method applied, and the path dependence of the actions taken. Reduced expected incremental net benefits of the GPEI and the substantial economic impacts of the COVID-19 pandemic pose large financial risks for the GPEI.
引用
收藏
页码:393 / 406
页数:14
相关论文
共 36 条
  • [1] [Anonymous], 2008, WHO GUID STAND EC EV
  • [2] Global health goals: lessons from the worldwide effort to eradicate poliomyelitis
    Aylward, RB
    Acharya, A
    England, S
    Agocs, M
    Linkins, J
    [J]. LANCET, 2003, 362 (9387) : 909 - 914
  • [3] Bart KJ, 1996, B WORLD HEALTH ORGAN, V74, P35
  • [4] Bureau of Labor Statistics U.S. Department of Labor ., 2020, CONS PRIC IND
  • [5] Global Polio Eradication Initiative, 2015, GLOB ER WILD POL TYP
  • [6] Cessation of Trivalent Oral Poliovirus Vaccine and Introduction of Inactivated Poliovirus Vaccine - Worldwide, 2016
    Hampton, Lee M.
    Farrell, Margaret
    Ramirez-Gonzalez, Alejandro
    Menning, Lisa
    Shendale, Stephanie
    Lewis, Ian
    Rubin, Jennifer
    Garon, Julie
    Harris, Jennifer
    Hyde, Terri
    Wassilak, Steven
    Patel, Manish
    Nandy, Robin
    Chang-Blanc, Diana
    [J]. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2016, 65 (35): : 934 - 938
  • [7] Health and Economic Outcomes Associated with Polio Vaccine Policy Options: 2019-2029
    Kalkowska, Dominika A.
    Thompson, Kimberly M.
    [J]. RISK ANALYSIS, 2021, 41 (02) : 364 - 375
  • [8] Updated Characterization of Outbreak Response Strategies for 2019-2029: Impacts of Using a Novel Type 2 Oral Poliovirus Vaccine Strain
    Kalkowska, Dominika A.
    Pallansch, Mark A.
    Wilkinson, Amanda
    Bandyopadhyay, Ananda S.
    Konopka-Anstadt, Jennifer L.
    Burns, Cara C.
    Oberste, M. Steven
    Wassilak, Steven G. F.
    Badizadegan, Kamran
    Thompson, Kimberly M.
    [J]. RISK ANALYSIS, 2021, 41 (02) : 329 - 348
  • [9] Expected Implications of Globally Coordinated Cessation of Serotype 3 Oral Poliovirus Vaccine (OPV) Before Serotype 1 OPV
    Kalkowska, Dominika A.
    Thompson, Kimberly M.
    [J]. RISK ANALYSIS, 2021, 41 (02) : 312 - 319
  • [10] Updated Characterization of Post-OPV Cessation Risks: Lessons from 2019 Serotype 2 Outbreaks and Implications for the Probability of OPV Restart
    Kalkowska, Dominika A.
    Pallansch, Mark A.
    Cochi, Stephen L.
    Kovacs, Stephanie D.
    Wassilak, Steven G. F.
    Thompson, Kimberly M.
    [J]. RISK ANALYSIS, 2021, 41 (02) : 320 - 328